Autoantibody-Mediated Depletion of IL-1RA in Still's Disease and Potential Impact of IL-1 Targeting Therapies.

Marie-Christin HoffmannGiulio CavalliNatalie FadleEleonora CantoniEvi RegitzOctavian FleserPhilipp KlemmMarina ZaksElisabeth StögerCorrado CampochiaroAlessandro TomelleriElena BaldisseraJörg Thomas BittenbringVincent ZimmerJochen PfeiferYvan FischerKlaus-Dieter PreussMoritz BewarderBernhard ThurnerSabrina FuehnerDirk FoellLorenzo DagnaChristoph KesselLorenz Thurner

Published in: Journal of clinical immunology (2024)

Autoantibodies neutralizing IL-1Ra may represent a novel patho-mechanism in a subgroup of Still's disease patients, which is sensitive to high-dose IL-1 blocking therapy.

Keyphrases

high dose
end stage renal disease
rheumatoid arthritis
ejection fraction
newly diagnosed
systemic lupus erythematosus
chronic kidney disease
low dose
disease activity
peritoneal dialysis
clinical trial
ankylosing spondylitis
mesenchymal stem cells
zika virus
stem cell transplantation
systemic sclerosis